Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura

Joan D. Beckman, Marian A. Rollins-Raval, Jay S. Raval, Yara A. Park, Marshall Mazepa, Alice Ma

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.

Original languageEnglish (US)
Pages (from-to)e270-e272
JournalAmerican journal of therapeutics
Volume25
Issue number2
DOIs
StatePublished - Mar 1 2018

Fingerprint

Purpura
Idiopathic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Purpura
Proteasome Inhibitors
Proteasome Endopeptidase Complex
Bortezomib
Research
Therapeutics

Cite this

Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura. / Beckman, Joan D.; Rollins-Raval, Marian A.; Raval, Jay S.; Park, Yara A.; Mazepa, Marshall; Ma, Alice.

In: American journal of therapeutics, Vol. 25, No. 2, 01.03.2018, p. e270-e272.

Research output: Contribution to journalArticle

Beckman, Joan D. ; Rollins-Raval, Marian A. ; Raval, Jay S. ; Park, Yara A. ; Mazepa, Marshall ; Ma, Alice. / Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura. In: American journal of therapeutics. 2018 ; Vol. 25, No. 2. pp. e270-e272.
@article{7898ecb17c774c79b942cea3ad56a798,
title = "Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura",
abstract = "The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.",
author = "Beckman, {Joan D.} and Rollins-Raval, {Marian A.} and Raval, {Jay S.} and Park, {Yara A.} and Marshall Mazepa and Alice Ma",
year = "2018",
month = "3",
day = "1",
doi = "10.1097/MJT.0000000000000517",
language = "English (US)",
volume = "25",
pages = "e270--e272",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura

AU - Beckman, Joan D.

AU - Rollins-Raval, Marian A.

AU - Raval, Jay S.

AU - Park, Yara A.

AU - Mazepa, Marshall

AU - Ma, Alice

PY - 2018/3/1

Y1 - 2018/3/1

N2 - The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.

AB - The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.

UR - http://www.scopus.com/inward/record.url?scp=85053903627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053903627&partnerID=8YFLogxK

U2 - 10.1097/MJT.0000000000000517

DO - 10.1097/MJT.0000000000000517

M3 - Article

C2 - 29293474

AN - SCOPUS:85053903627

VL - 25

SP - e270-e272

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 2

ER -